Bisenieks Egils, Vigante Brigita, Petrovska Ramona, Turovska Baiba, Muhamadejev Ruslan, Soloduns Vitalijs, Velena Astrida, Pajuste Karlis, Saso Luciano, Klovins Janis, Duburs Gunars, Mandrika Ilona
Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia.
Latvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia.
Pharmaceuticals (Basel). 2021 Sep 28;14(10):987. doi: 10.3390/ph14100987.
The paradigm of ligand-receptor interactions postulated as "one compound-one target" has been evolving; a multi-target, pleiotropic approach is now considered to be realistic. Novel series of 1,4,5,6,7,8-hexahydro-5-oxoquinolines, pyranopyrimidines and S-alkyl derivatives of pyranopyrimidines have been synthesized in order to characterise their pleiotropic, multitarget activity on the FFA3/GPR41, FFA2/GPR43, and HCA2/GPR109A receptors. Hexahydroquinoline derivatives have been known to exhibit characteristic activity as FFA3/GPR41 ligands, but during this study we observed their impact on FFA2/GPR43 and HCA2/GPR109A receptors as well as their electron-donating activity. Oxopyranopyrimidine and thioxopyranopyrimidine type compounds have been studied as ligands of the HCA2/GPR109A receptor; nevertheless, they exhibited equal or higher activity towards FFA3/GPR41 and FFA2/GPR43 receptors. S-Alkyl derivatives of pyranopyrimidines that have not yet been studied as ligands of GPCRs were more active towards HCA2/GPR109A and FFA3/GPR41 receptors than towards FFA2/GPR43. Representative compounds from each synthesized series were able to decrease the lipopolysaccharide-induced gene expression and secretion of proinflammatory cytokines (IL-6, TNF-α) and of a chemokine (MCP-1) in THP-1 macrophages, resembling the effect of HCA2/GPR109A ligand niacin and the endogenous ligand propionate. This study revealed groups of compounds possessing multitarget activity towards several receptors. The obtained data could be useful for further development of multitarget ligands.
假定为“一种化合物-一个靶点”的配体-受体相互作用模式一直在演变;现在认为多靶点、多效性方法是切实可行的。已合成了一系列新型的1,4,5,6,7,8-六氢-5-氧代喹啉、吡喃并嘧啶以及吡喃并嘧啶的S-烷基衍生物,以表征它们对游离脂肪酸受体3/ G蛋白偶联受体41(FFA3/GPR41)、游离脂肪酸受体2/ G蛋白偶联受体43(FFA2/GPR43)和羟基羧酸受体2/ G蛋白偶联受体109A(HCA2/GPR109A)受体的多效性、多靶点活性。六氢喹啉衍生物作为FFA3/GPR41配体已显示出特征性活性,但在本研究中,我们观察到它们对FFA2/GPR43和HCA2/GPR109A受体的影响以及它们的供电子活性。氧代吡喃并嘧啶和硫代吡喃并嘧啶类化合物已作为HCA2/GPR109A受体的配体进行了研究;然而,它们对FFA3/GPR41和FFA2/GPR43受体表现出同等或更高的活性。尚未作为G蛋白偶联受体配体进行研究的吡喃并嘧啶的S-烷基衍生物对HCA2/GPR109A和FFA3/GPR41受体的活性比对FFA2/GPR43受体的活性更高。每个合成系列的代表性化合物能够降低脂多糖诱导的THP-1巨噬细胞中促炎细胞因子(白细胞介素-6、肿瘤坏死因子-α)和趋化因子(单核细胞趋化蛋白-1)的基因表达和分泌,类似于HCA2/GPR109A配体烟酸和内源性配体丙酸的作用。本研究揭示了对几种受体具有多靶点活性的化合物组。所获得的数据可能有助于多靶点配体的进一步开发。